CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00594815
NCT00594815N/ACompleted
CompareCT.gov

A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 16, 2008·Updated Apr 6, 2017

In Brief

A clinical study evaluating Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine for Lymphoma. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. The investigators hope that the addition of rituximab will improve the control of the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNorthwestern Memorial Hospital, Columbia University, Kentuckiana Cancer Institute, University of Virginia, University of Vermont

Timeline

N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2008
Enrollment StartAug 28, 2002
Primary CompletionFeb 23, 2016
TodayJul 2, 2026
Enrollment to primary: 13.5 yearsPosted 18.5 years ago

Interventions

Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristinedrug

Immunochemotherapy